Abstract
Myocarditis is an inflammation of the myocardium which often follows microbial infections and is a significant cause of sudden unexpected death in the young (<40 years of age) and an underlying cause of dilated cardiomyopathy. Although histologically, the disease is usually associated with infiltration of the myocardium with either eosinophils or leukocytes, use of immunosuppression is controversial outside of giant cell myocarditis and has been found to be of limited value in lymphocytic myocarditis. The relatively limited response might reflect the need for host immunity to control persistent virus infection in the heart which may be the predominant cause of the chronic myocarditis and dilated cardiomyopathy. Treating the persistent virus infection with interferon-beta improved cardiac function in a clinical trial. However, classic immunosuppressive drugs, such as cyclosporine A and cyclophosphamide, are not effective against all types of immunity and experimental myocarditis models have shown that certain immunopathogenic forms of the disease are resistant to these immunosuppressive agents. Understanding the molecular mechanisms underlying the pathogenesis of this disease and the various infectious agents which can cause it will be essential for developing effective therapeutic agents.
Keywords: Myocarditis, dilated cardiomyopathy, picornaviruses, autoimmunity, fibrosis, persistent infection, immunosuppression, endothelial-mesenchymal transition.
Current Pharmaceutical Design
Title:Viral Myocarditis and Dilated Cardiomyopathy: Etiology and Pathogenesis
Volume: 22 Issue: 4
Author(s): Sally A. Huber
Affiliation:
Keywords: Myocarditis, dilated cardiomyopathy, picornaviruses, autoimmunity, fibrosis, persistent infection, immunosuppression, endothelial-mesenchymal transition.
Abstract: Myocarditis is an inflammation of the myocardium which often follows microbial infections and is a significant cause of sudden unexpected death in the young (<40 years of age) and an underlying cause of dilated cardiomyopathy. Although histologically, the disease is usually associated with infiltration of the myocardium with either eosinophils or leukocytes, use of immunosuppression is controversial outside of giant cell myocarditis and has been found to be of limited value in lymphocytic myocarditis. The relatively limited response might reflect the need for host immunity to control persistent virus infection in the heart which may be the predominant cause of the chronic myocarditis and dilated cardiomyopathy. Treating the persistent virus infection with interferon-beta improved cardiac function in a clinical trial. However, classic immunosuppressive drugs, such as cyclosporine A and cyclophosphamide, are not effective against all types of immunity and experimental myocarditis models have shown that certain immunopathogenic forms of the disease are resistant to these immunosuppressive agents. Understanding the molecular mechanisms underlying the pathogenesis of this disease and the various infectious agents which can cause it will be essential for developing effective therapeutic agents.
Export Options
About this article
Cite this article as:
Huber A. Sally, Viral Myocarditis and Dilated Cardiomyopathy: Etiology and Pathogenesis, Current Pharmaceutical Design 2016; 22 (4) . https://dx.doi.org/10.2174/1381612822666151222160500
DOI https://dx.doi.org/10.2174/1381612822666151222160500 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Smoking and Cardiovascular System: Cellular Features of the Damage
Current Pharmaceutical Design Fibrosis as a Therapeutic Target Post-Myocardial Infarction
Current Pharmaceutical Design Salvia miltiorrhiza: A Potential Red Light to the Development of Cardiovascular Diseases
Current Pharmaceutical Design Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics
Current Medicinal Chemistry Antivitamin K Drugs in Stroke Prevention
Current Vascular Pharmacology Novel Strategies to Delineate Matrix Metalloproteinase (MMP)-Substrate Relationships and Identify Targets to Block MMP Activity
Mini-Reviews in Medicinal Chemistry Pharmacologically Targeting the Primary Defect and Downstream Pathology in Duchenne Muscular Dystrophy
Current Gene Therapy Pharmacologic Therapy in Growth Hormone Disorders and the Heart
Current Medicinal Chemistry Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines
Current Drug Metabolism The Effect of Licorice Drink on the Systemic Exposure of Verapamil in Rabbits
Drug Metabolism Letters Searching for Phytoinsulins as Cardiovascular Protector in Metabolic Syndrome
Current Pharmaceutical Design Periostin as a Heterofunctional Regulator of Cardiac Development and Disease
Current Genomics Re-Discovering PDE3 Inhibitors - New Opportunities for a Long Neglected Target
Current Topics in Medicinal Chemistry Highlighting Exosomes’ Function in Cardiovascular Diseases
Current Cardiology Reviews Regression of Oxidative Stress by Targeting eNOS and Nrf2/ARE Signaling: A Guided Drug Target for Cardiovascular Diseases
Current Topics in Medicinal Chemistry Species Differences in Hepatocyte-Directed Gene Transfer: Implications for Clinical Translation
Current Gene Therapy Chelating Agents for Metal Intoxication
Current Medicinal Chemistry Big Data and Genome Editing Technology: A New Paradigm of Cardiovascular Genomics
Current Cardiology Reviews Stem Cells as a Novel Tool for Drug Screening and Treatment of Degenerative Diseases
Current Pharmaceutical Design Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation
Current Pharmaceutical Design